Tetraphase Pharmaceuticals, Inc. (TTPH)


Stock Price Forecast

July 28, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Tetraphase Pharmaceuticals, Inc. chart...

About the Company

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

67

CEO

Larry Edwards

Exchange

NASDAQ

Website

http://www.tphase.com

$8M

Total Revenue

67

Employees

$11M

Market Capitalization

-0.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TTPH News

Douglas G. Cole's Net Worth

9d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., TETRAPHASE PHARMACEUTICALS INC, AGIOS PHARMACEUTICALS INC, Receptos, Inc., Editas Medicine ...

Stephen J Hoffman's Net Worth

29d ago, source: Benzinga.com

Who is Stephen J Hoffman? Stephen J Hoffman does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which ...

MRNS Marinus Pharmaceuticals, Inc.

5h ago, source: Seeking Alpha

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

10d ago, source:

Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards ...

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

11h ago, source: Zacks.com on MSN

It was a busy week for the biotech sector, with lots of study data readouts and regulatory updates. Among these, Praxis ...

Catalyst Pharmaceuticals

1d ago, source: Forbes

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...

ARDS Aridis Pharmaceuticals, Inc.

6d ago, source: Seeking Alpha

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.

Vertex Pharmaceuticals Inc VRTX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Alnylam Pharmaceuticals

2d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Vanda Pharmaceuticals Inc.

7d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Q4 2023 Cumberland Pharmaceuticals Inc Earnings Call

22d ago, source: Yahoo Finance

Todd Anthony; VP & Organizational Development; Cumberland Pharmaceuticals Inc. Operator Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 financial report and company. Our call is ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript

28d ago, source: Yahoo Finance

Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33. MIRM isn't one of the 30 most popular stocks among hedge funds at the end of the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...